IMS CORE lab teams up with Cristal Therapeutics
Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.
The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.
For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/
Also read
-
Cells, pigments or food: looking through the eyes of a microscope
How do you make the tiniest cells visible? At the Microscopy CORE Lab. Kèvin Knoops leads this research platform for light and electron microscopy.
-
Gut bacterium may help maintain weight loss
Researchers at Maastricht University and Wageningen University & Research have made a promising discovery in the fight against obesity. A new clinical study shows that a specific gut bacterium may help limit weight regain after dieting.UM news
-
Collaborative Maastricht University team receives Open Science NL funding
A multidisciplinary team of UM researchers and support staff has been awarded a €250,000 grant from Open Science NL. Their project will highlight an often-overlooked part of academic research: the people who support it behind the scenes.
